Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb 20;22(2):e14122.
doi: 10.2196/14122.

Concordance Between Watson for Oncology and a Multidisciplinary Clinical Decision-Making Team for Gastric Cancer and the Prognostic Implications: Retrospective Study

Yulong Tian  1 , Xiaodong Liu  1 , Zixuan Wang  2 , Shougen Cao  1 , Zimin Liu  3 , Qinglian Ji  4 , Zequn Li  1 , Yuqi Sun  1 , Xin Zhou  1 , Daosheng Wang  1 , Yanbing Zhou  1
Affiliations

Concordance Between Watson for Oncology and a Multidisciplinary Clinical Decision-Making Team for Gastric Cancer and the Prognostic Implications: Retrospective Study

Yulong Tian et al. J Med Internet Res. .

Abstract

Background: With the increasing number of cancer treatments, the emergence of multidisciplinary teams (MDTs) provides patients with personalized treatment options. In recent years, artificial intelligence (AI) has developed rapidly in the medical field. There has been a gradual tendency to replace traditional diagnosis and treatment with AI. IBM Watson for Oncology (WFO) has been proven to be useful for decision-making in breast cancer and lung cancer, but to date, research on gastric cancer is limited.

Objective: This study compared the concordance of WFO with MDT and investigated the impact on patient prognosis.

Methods: This study retrospectively analyzed eligible patients (N=235) with gastric cancer who were evaluated by an MDT, received corresponding recommended treatment, and underwent follow-up. Thereafter, physicians inputted the information of all patients into WFO manually, and the results were compared with the treatment programs recommended by the MDT. If the MDT treatment program was classified as "recommended" or "considered" by WFO, we considered the results concordant. All patients were divided into a concordant group and a nonconcordant group according to whether the WFO and MDT treatment programs were concordant. The prognoses of the two groups were analyzed.

Results: The overall concordance of WFO and the MDT was 54.5% (128/235) in this study. The subgroup analysis found that concordance was less likely in patients with human epidermal growth factor receptor 2 (HER2)-positive tumors than in patients with HER2-negative tumors (P=.02). Age, Eastern Cooperative Oncology Group performance status, differentiation type, and clinical stage were not found to affect concordance. Among all patients, the survival time was significantly better in concordant patients than in nonconcordant patients (P<.001). Multivariate analysis revealed that concordance was an independent prognostic factor of overall survival in patients with gastric cancer (hazard ratio 0.312 [95% CI 0.187-0.521]).

Conclusions: The treatment recommendations made by WFO and the MDT were mostly concordant in gastric cancer patients. If the WFO options are updated to include local treatment programs, the concordance will greatly improve. The HER2 status of patients with gastric cancer had a strong effect on the likelihood of concordance. Generally, survival was better in concordant patients than in nonconcordant patients.

Keywords: Watson for Oncology; artificial intelligence; concordance; gastric cancer; multidisciplinary team.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: None declared.

Figures

Figure 1
Figure 1
Flow diagram of the patient selection process. MDT: multidisciplinary team; WFO: Watson for Oncology.
Figure 2
Figure 2
Overall survival in all patients. MDT: multidisciplinary team.
Figure 3
Figure 3
Overall survival in stage II patients. MDT: multidisciplinary team.
Figure 4
Figure 4
Overall survival in stage III patients. MDT: multidisciplinary team.
Figure 5
Figure 5
Overall survival in stage IV patients. MDT: multidisciplinary team.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov 12;68(6):394–424. doi: 10.3322/caac.21492. doi: 10.3322/caac.21492. - DOI - DOI - PubMed
    1. Chen W, Sun K, Zheng R, Zeng H, Zhang S, Xia C, Yang Z, Li H, Zou X, He J. Cancer incidence and mortality in China, 2014. Chin J Cancer Res. 2018 Feb;30(1):1–12. doi: 10.21147/j.issn.1000-9604.2018.01.01. doi: 10.21147/j.issn.1000-9604.2018.01.01. - DOI - DOI - PMC - PubMed
    1. Hollunder S, Herrlinger U, Zipfel M, Schmolders J, Janzen V, Thiesler T, Güresir E, Schröck A, Far F, Pietsch T, Pantelis D, Thomas D, Vornholt S, Ernstmann N, Manser T, Neumann M, Funke B, Schmidt-Wolf IGH. Cross-sectional increase of adherence to multidisciplinary tumor board decisions. BMC Cancer. 2018 Sep 29;18(1):936. doi: 10.1186/s12885-018-4841-4. https://bmccancer.biomedcentral.com/articles/10.1186/s12885-018-4841-4 - DOI - DOI - PMC - PubMed
    1. Terry HP, Hulsing J, Grant M, Powell D, Mubayi P, Syed W. EQUITY RESEARCH. Research Compliance, 200 West Street, New York, NY 10282: The Goldman Sachs Group, Inc; 2016. Nov 14, [2019-02-26]. Artificial Intelligence AI, Machine Learning and Data Fuel the Future of Productivity https://www.gspublishing.com/content/research/en/reports/2019/09/04/a0d3....
    1. Curioni-Fontecedro A. A new era of oncology through artificial intelligence. ESMO Open. 2017;2(2):e000198. doi: 10.1136/esmoopen-2017-000198. http://europepmc.org/abstract/MED/28761754 - DOI - PMC - PubMed